2022 Ljubljana, Slovenia

IV-04 Vanessa Baier
PBPK model-guided assessment of a liver function test
Thursday 15:00-16:30
IV-05 Pavel Balazki
PB-QSP model of type 2 diabetes for individualized prediction of treatment combination outcomes with metformin, DPP4i, and SGLT2i.
Thursday 15:00-16:30
IV-06 Sara Bettonte
Cabotegravir pharmacokinetics after oral and intramuscular administration using physiologically based pharmacokinetic modelling
Thursday 15:00-16:30
IV-10 Letizia Carrara
Prospective predictions of drug pharmacokinetics and food effect in pediatrics via PBPK modelling
Thursday 15:00-16:30
IV-13 Marylore Chenel
Physiologically based pharmacokinetic (PBPK) modelling of cabotegravir (CAB) to support design of microarray patches (MAPs) for the treatment of HIV positive children
Thursday 15:00-16:30
IV-17 Yumi Cleary
Physiologically-based pharmacokinetic modelling of basmisanil to evaluate CYP3A mediated victim and perpetrator drug-drug interaction propensity
Thursday 15:00-16:30
IV-27 Laura Fuhr
Peeling the grapefruit – investigating the drug interaction potential of grapefruit juice as CYP3A4 inhibitor using physiologically-based pharmacokinetic modeling
Thursday 15:00-16:30
IV-39 Helena Loer
Dose Adaptations for Drug-Gene and Drug-Drug Interactions involving Clopidogrel – A Physiologically based Pharmacokinetic (PBPK) Modeling Approach
Thursday 15:00-16:30
IV-42 Fatima Zahra Marok
Physiologically-based pharmacokinetic modeling of drug-drug interactions with ketoconazole and its metabolite deacetyl-ketoconazole
Thursday 15:00-16:30
IV-44 Nina Nauwelaerts
Physiologically-Based Pharmacokinetic (PBPK) Modelling to Predict Human Milk Exposure to Sildenafil and Bosentan: a contribution from the ConcePTION Project
Thursday 15:00-16:30
IV-46 Fiona Plait
Physiologically Based Pharmacokinetic Modeling of a CYP3A4-Mediated Drug-Drug Interaction: Prediction of Victim of Induction, not Inhibition, with a Moderate Fraction Metabolized by CYP3A4
Thursday 15:00-16:30
IV-47 Alicja Puszkiel
A minimal PBPK model for plasma and cerebrospinal fluid pharmacokinetics of trastuzumab in patients with leptomeningeal carcinomatosis
Thursday 15:00-16:30
IV-48 Javier Reig-López
A Physiologically Based Pharmacokinetic Model for Open Acid and Lactone Forms of Atorvastatin and Its Two Metabolites
Thursday 15:00-16:30
IV-51 Ayatallah Saleh
Elucidating the complex pharmacokinetics of voriconazole leveraging a middle-out approach
Thursday 15:00-16:30
IV-52 Morwarid Shahhossini
Development of a physiologically based pharmacokinetic model of Ciprofloxacin in ovine septic shock
Thursday 15:00-16:30
IV-53 Yesong Shin
Population pharmacokinetic modelling for enterohepatic circulation of leflunomide in healthy Korean
Thursday 15:00-16:30
IV-55 Erik Sjögren
A platform for mechanistic modelling of subcutaneous administration with the effect of immunogenicity within the Open Systems Pharmacology framework
Thursday 15:00-16:30
IV-61 Eunsol Yang
Prediction of gastric pH-mediated drug exposure changes using physiologically based pharmacokinetic modeling: A case study of itraconazole
Thursday 15:00-16:30